Large Map
  • Healthy Living
Cloning stem cells: What does it mean?
Cloning stem cells: What does it mean?

Creating an embryo just from an egg and a skin cell seems like …

5 ways to handle chronic pain
5 ways to handle chronic pain

While pain medications play an important role in the treatment …

Mediterranean diet is brain food
Mediterranean diet is brain food

Researchers found that study participants who were on a …

France: Drugmaker on trial, suspected in deaths
French drugmaker suspected in deaths

The makers of a diabetes and weight loss drug suspected in the …

Health group didn't disclose HIV tests, apologizes
Health group didn't disclose HIV tests

Kaiser Permanente Northwest is apologizing to nearly 6,500 …

Advertisement

McKesson to pay $151M to settle drug-pricing suit

Updated: Friday, 27 Jul 2012, 4:56 PM EDT
Published : Friday, 27 Jul 2012, 4:56 PM EDT

SAN FRANCISCO (AP) - Twenty-nine states have reached a $151 million settlement in a lawsuit alleging one of the country's largest drug wholesalers inflated prices for hundreds of prescription drugs, officials said Friday.

The agreement with San Francisco-based McKesson Corp. settles allegations that the company deliberately inflated drug prices by as much as 25 percent, causing the states' Medicaid programs to overpay millions of dollars in reimbursements.

An investigation by state and federal agencies found that McKesson inflated the prices of more than 1,400 brand-name drugs, including these commonly prescribed medications such as Adderall, Allegra, Ambien, Celexa, Lipitor, Neurontin, Prevacid, Prozac and Ritalin, officials said.

California, where the alleged overpayments went on from August 2001 to December 2009, will receive about $24 million of the settlement, said state Attorney General Kamala Harris.

"In these difficult budget times, it is crucial that California's scarce public resources support the urgent needs of our state," Harris said in a statement. "We cannot allow dollars meant for patients to be diverted to inflate corporate profits."

McKesson representative Kris Fortner said the claims against the company are without merit, but "given the inherent uncertainty of litigation, we determined that this settlement was in the best interest of our employees, customers, suppliers and shareholders."

"We did not manipulate drug prices and did not violate any laws," Fortner said.

The settlement stems from a 2005 whistleblower lawsuit that was filed under federal and states' false claims statutes. It alleged that McKesson inflated average wholesale prices reported to First Data Bank, which many state Medicaid programs use to set payment rates for pharmaceutical reimbursement.

The federal government settled its portion of the lawsuit for more than $187 million in April.

New York will receive $64 million in restitution as part of the settlement announced Friday, said state Attorney General Eric Schneiderman.

"Pharmaceutical distribution companies are not above the law. This settlement holds McKesson accountable for attempting to make millions of dollars in illegal profits," Schneiderman said.

Besides California and New York, states covered in the settlement include Arkansas, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Maine, Michigan, Minnesota, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, North Dakota, Pennsylvania, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wyoming. The District of Columbia also was covered.
 

  • Comments

Comments WLFI.com is migrating to a more stable commenting system called DISQUS. This system is used by CNN, TIME, FOX News, numerous blogging sites and has over 75 Million registered users. Unfortunately we can't migrate our current user accounts to this new system.

To sign up for a DISQUS account, click the DISQUS button just below and to the right and then click Login.

DISQUS lets you login with several different options, including Facebook, Google, Twitter, Yahoo or OpenID. We expect it to allow more conversation and better moderation. If you have any questions, please feel free to comment below.

 

blog comments powered by Disqus

Advertisement
Advertisement